Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
about
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerPersistent androgen receptor addiction in castration-resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerDarolutamide (ODM-201) for the treatment of prostate cancerAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsTargeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Synthesis and evaluation of novel thiazole-based derivatives as selective inhibitors of DNA-binding domain of the androgen receptor.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Prostate cancer: Developing novel approaches to castration-sensitive disease.Progress in the mechanism and drug development of castration-resistant prostate cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Androgen receptor variation affects prostate cancer progression and drug resistance.Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer.Clinical relevance of androgen receptor alterations in prostate cancer.Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.Recent Advances in Prostate Cancer Treatment and Drug Discovery.Patent Highlights October-November 2016.Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistanceEnzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
P2860
Q26750620-92987325-5B1A-4E51-8C44-4DE3B4EF8B7AQ26777163-C63F40A7-BA18-4B5D-8DAF-1EBCC348DD89Q26796568-4C0D2E28-F90B-49EE-8105-5F62351F95AEQ28067556-E95EF60B-7251-4DBE-B239-E7EE73A75448Q34556466-234A4FA8-0E31-4A32-A264-E3C04736C536Q36398998-ADF3EA40-F25F-4092-AC4A-95FB9DFBD2F0Q36905832-B5CB634D-F7DD-485A-8077-C176AE6E73E4Q37496652-79C866B1-6ACD-4E17-823A-7826AA1C0721Q38698469-B5166FEA-A97B-4E5D-8533-9FA7CA0BC6E2Q38765489-E8A60261-1EC4-4E69-B0CD-07BE6F59CA73Q38775459-0DE010D9-3C11-41F0-B2DE-C5AD9123D9BBQ38801270-CC381DD1-5AF1-40A1-9254-CD05D77E3A71Q38826609-A4324B5C-7C60-45E9-AF43-7F7B2A4DA00CQ38865487-5A501F12-1FF3-4F2C-B575-1809E7E5A6A6Q38977288-35E4DE86-1D73-4FBC-8B52-962A8DFD2208Q42358750-D436461B-BFEA-4AFD-80C1-4C4A6AF6124CQ42377108-6800ED7C-ED56-47D5-B67A-DF82C8C675C5Q44964713-83AA6377-214D-43A9-AEEE-E37A7F767BD3Q50074169-64615AA1-0E11-4C06-9E47-04AB0BA319AAQ52677958-AD742ABA-EBE2-4D8F-8237-658662CF85FAQ54111821-961CBB01-0AA3-411C-AC67-839F922BCF44Q54380711-3FB74569-6B93-48D5-88A9-697A40EF3B1AQ57135992-6ED38D92-72D4-4943-8E0E-1338705C4626Q58698705-3B126330-8304-49A7-AF18-47EC66CB507B
P2860
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@ast
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@en
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@nl
type
label
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@ast
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@en
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@nl
prefLabel
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@ast
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@en
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@nl
P2093
P2860
P356
P1433
P1476
Discovery of ODM-201, a new-ge ...... cted prostate cancer therapies
@en
P2093
Anu-Maarit Moilanen
Gerd Wohlfahrt
Jorma J Palvimo
Laura Ravanti
Olli P Törmäkangas
Pekka J Kallio
Pirjo S Nykänen
Reetta Riikonen
Riikka Oksala
P2860
P2888
P356
10.1038/SREP12007
P407
P577
2015-07-03T00:00:00Z
P5875
P6179
1049941472